Risk of Cardiovascular Disease Similar in Dual E-Cigarette and Traditional Cigarette Users: Study

May.09.2022
Risk of Cardiovascular Disease Similar in Dual E-Cigarette and Traditional Cigarette Users: Study
Using both traditional cigarettes and e-cigarettes may not lower cardiovascular disease risk and may have harmful health effects.

Key points of the research:

 

A study of over 24,000 American adults has found that using both traditional cigarettes and electronic cigarettes does not decrease the risk of cardiovascular disease and may lead to harmful health effects similar to smoking. Those who use both traditional cigarettes and e-cigarettes do not have significantly lower risks of heart attacks, heart failure, or strokes compared to those who only smoke, nor did they report any self-reported cardiovascular disease outcomes. While those who use only e-cigarettes reported fewer cardiovascular events than those who only smoked traditional cigarettes, the number of reported heart events was too small to draw clear conclusions on the effects of solely using e-cigarettes in the study sample. Researchers note the need for more long-term data on e-cigarette use. The study was published on May 6, 2022, in the flagship peer-reviewed journal "Circulation" of the American Heart Association.

 

Traditional cigarette smoking is widely recognized as a major cause of serious health conditions. According to updated statistics from the American Heart Association on heart disease and stroke in 2022, nearly one-fifth of all deaths in the United States each year are attributed to smoking and exposure to secondhand smoke. Electronic cigarettes, which contain numerous toxic chemicals, are increasingly popular as another way for people to consume nicotine.

 

According to Dr. Stokes, the lead investigator and senior author of the study, Andrew C. stated, "The risk of cardiovascular disease associated with dual use of traditional combustible cigarettes and electronic cigarettes, similar to smoking, is an important finding because many Americans are using e-cigarettes in an attempt to reduce smoking as they perceive the risk of e-cigarettes to be lower." Dr. Stokes, Assistant Professor in the Department of Global Health at the Boston University School of Public Health, further explained that "People are attempting to transition from traditional cigarettes to e-cigarettes, and dual use of both products is common.

 

To investigate the relationship between cardiovascular disease, the use of electronic and traditional cigarettes, and their combined use, researchers examined data from the Population Assessment of Tobacco and Health (PATH) study. This nationally representative study collected self-reported health and nicotine product usage information from over 24,000 adults between 2013 and 2019, across five annual waves. After adjusting for age, gender, and race/ethnicity, the study focused on adults, over 50% of whom were under the age of 35, and 51% of whom were female.

 

Participants who reported smoking during any round of data collection after smoking over 100 combustible cigarettes in their lifetime were classified as smokers. E-cigarette users were identified based on self-reported e-cigarette use during any round of data collection. The groups were classified as follows: 1) current non-users of e-cigarettes or combustible cigarettes (14,832 individuals; this group may include former smokers or former e-cigarette users); 2) e-cigarette use only (822 individuals); 3) combustible cigarette use only (6,515 individuals); or 4) mixed use of combustible cigarettes and e-cigarettes (1,858 individuals).

 

The analysis defined cardiovascular events as either self-reported diagnoses of a heart attack, coronary artery bypass surgery, heart failure, other heart conditions, or stroke within the past 12 months. The researchers also examined the specific outcomes of self-reported heart attack, heart failure, or stroke. The review identified over 1,480 cases of cardiovascular disease and more than 500 cases of heart attack, heart failure, or stroke.

 

Analysis of all study participants revealed:

 

Compared to those who only smoke traditional cigarettes, individuals who smoke both traditional cigarettes and use e-cigarettes do not have a significant difference in the risk of developing cardiovascular diseases such as heart attacks, heart failure, or strokes. Those who only use e-cigarettes or use both traditional and e-cigarettes are younger than those who do not use these products at all: 62% of e-cigarette only users and 54% of dual users are under the age of 35, compared to 51% of non-users. The researchers note that only using e-cigarettes has a reported 30%-40% lower risk of self-reported cardiovascular disease events compared to traditional smoking, although this association is important for any cardiovascular outcome, including congenital heart disease or myocarditis (e-cigarette users reported 41 events, compared to 569 for smokers), rather than specifically for heart attacks, heart failure, or strokes (15 events reported by e-cigarette users, compared to 242 for smokers). Considering the limited amount of self-reported data from e-cigarette users, the researchers conclude that more data is needed in this field.

 

Even though the PATH study is providing basic longitudinal data on traditional cigarette and e-cigarette use and cardiovascular events, the data is self-reported, the study duration is short, and the event rates are still low - especially among young people. As e-cigarette use is still relatively new, there is currently not a vast amount of long-term evidence to determine the ultimate risks associated with using these products over time. Therefore, we look forward to obtaining more data from this and other ongoing studies. It is important to remember that even with traditional cigarette use, it took decades of use and monitoring to provide us with the evidence we now have to confirm the significant harm of combustible cigarettes," said Rose Marie Robertson, MD, FAHA, American Heart Association deputy chief science and medical officer and co-director of the Tobacco Regulation and Addiction Center, which supports the study.

 

People should be aware that electronic cigarettes contain addictive nicotine and toxic chemicals that may have adverse effects on their cardiovascular system and overall health.

 

A key limitation noted by researchers in this study is the low incidence of individual and cardiovascular events in the group of exclusive e-cigarette users. While only 15 individuals who exclusively used e-cigarettes reported diagnoses of heart attack, heart failure, or stroke, the small number of individuals and events makes it difficult to draw definite conclusions about the impact of exclusive e-cigarette use on the study sample.

 

Stokes has stated that many smokers who attempt to quit using e-cigarettes actually continue to use both products, becoming dual users, and as a result, their cardiovascular risks do not decrease. "We are concerned that any recommendations for using e-cigarettes to quit smoking may lead to an increase in dual use among young people and never smokers, as well as initiation of e-cigarette use.

 

Electronic cigarettes are not approved by the US Food and Drug Administration (FDA) for smoking cessation. We urge anyone who smokes and is interested in quitting to discuss FDA-approved, effective smoking cessation options with their doctor and healthcare team," said Robertson.

 

The Tobacco Regulation Science Center of the American Heart Association received funding for this study through grants from the United States government. The Center for Tobacco Products at the Food and Drug Administration obtained the funding through the National Heart, Lung, and Blood Institute at the National Institutes of Health. The American Heart Association is working closely with investigators from institutions across the nation through this Center to conduct research aimed at increasing existing knowledge about the health effects of smoking and nicotine-containing products (including e-cigarettes). These findings can help provide information for public health and tobacco product regulation.

 

The co-authors of this work are Jonathan B. Bellows, B.A.; Wubin Xie, Dr.P.H., M.P.H.; Alyssa F. Halbower, Dr.P.H., M.P.H.; Naomi M. Hamburg, M.D.; Michael J. Blaha, M.D., M.P.H.; Aruni Bhatnagar, Ph.D., FAHA; and Emelia J. Benjamin, M.D., Sc.M., FAHA.

 

Source: American Heart Association.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
Philip Morris International's IQOS has extended its partnership with electronic-music event brand ZAMNA to Spain, setting up a House of IQOS at ZAMNA Madrid. Vogue España and Time Out Madrid subsequently published branded content clearly labeled as collaborations with IQOS. PMI has also expanded its company-owned IQOS boutique network in Spain to seven cities this year. The company says IQOS's adjusted heated-tobacco market share in Europe reached 12.6% in the first quarter of 2026, with Spain among its stronger-performing European markets.
Sep.20
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
At InterTabac 2026 in Dortmund, China Tobacco International (HK) Company Limited (CTIHK) is exhibiting across two separate booths in Hall 5 and Hall 4. Products observed by 2Firsts include heated tobacco products, nicotine pouches, Chinese cigars and tobacco leaf. Nicotine pouch products on display include TOOP, Shuangxi and Ashima.
Market
Sep.16
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives